Last reviewed · How we verify
mRNA-1083 Composition 1 Dose A Lot B — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
mRNA-1083 Composition 1 Dose A Lot B (mRNA-1083 Composition 1 Dose A Lot B) — ModernaTX, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| mRNA-1083 Composition 1 Dose A Lot B TARGET | mRNA-1083 Composition 1 Dose A Lot B | ModernaTX, Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- mRNA-1083 Composition 1 Dose A Lot B CI watch — RSS
- mRNA-1083 Composition 1 Dose A Lot B CI watch — Atom
- mRNA-1083 Composition 1 Dose A Lot B CI watch — JSON
- mRNA-1083 Composition 1 Dose A Lot B alone — RSS
Cite this brief
Drug Landscape (2026). mRNA-1083 Composition 1 Dose A Lot B — Competitive Intelligence Brief. https://druglandscape.com/ci/mrna-1083-composition-1-dose-a-lot-b. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab